Table 1

Information provided in the guidelines: A) Conflict of interest statements and primary topics. B) Sponsorship information.

A)
CONFLICT OF INTEREST AND PRIMARY TOPICALL GUIDELINES, N (%)*(N = 196)ALL GUIDELINES EXCLUDING SUBSECTIONS, N (%)*(N = 119)
Conflict of interest statement
  • In guideline61 (31.1)28 (23.5)
  • Separate website9 (4.6)9 (7.6)
  • Not provided126 (64.3)82 (68.9)
Primary topic of guideline
  • Public health42 (21.4)15 (12.6)
  • Infectious disease37 (18.9)8 (6.7)
  • Pediatrics20 (10.2)20 (16.8)
  • Neurology11 (5.6)5 (4.2)
  • Cardiology10 (5.1)10 (8.4)
  • Oncology9 (4.6)9 (7.6)
  • Pulmonology9 (4.6)9 (7.6)
  • Endocrinology8 (4.1)8 (6.7)
  • Obstetrics and gynecology8 (4.1)8 (6.7)
  • Psychiatry6 (3.1)6 (5.0)
  • Nonspecific26 (13.3)11 (9.2)
  • Other10 (5.1)10 (8.4)
B)
TYPE OF SPONSORALL GUIDELINES, N (%)* TOTAL NO. OF SPONSORS, N = 446§||ALL GUIDELINES EXCLUDING SUBSECTIONS, N (%) TOTAL NO. OF SPONSORS, N = 236§||
Foundation or charity12 (2.7)12 (5.1)
Government147 (32.9)91 (38.6)
Society or association77 (17.3)65 (27.5)
Professional body14 (3.1)14 (5.9)
Medical industry177 (39.7)41 (17.4)
Other18 (4.0)12 (5.1)
Unclear1 (0.2)1 (0.4)
  • * Percentages do not add to 100 owing to rounding.

  • Four guidelines filed each of their subsections (6 to 29 subsections for each) as separate guidelines. In a secondary analysis, these subsections were eliminated.

  • Other category includes gastroenterology (n = 3), geriatrics (n = 2), hematology (n = 2), nephrology (n = 1), rheumatology and sports medicine (n = 1), and urology (n = 1).

  • § Numbers of guideline sponsors represent the total number of sponsors. Some guidelines had up to 16 sponsors with multiple sponsors of the same type (eg, an individual guideline might have 2 different government-related sponsors, 5 sponsors from different societies or associations, and 5 different sponsors from the same industry).

  • || Mean number of sponsors (range) for all guidelines was 2.3 (1–16) and for all guidelines excluding subsections was 2 (1–16).